Targeting the miR-98-5p/IGF2BP3/SLC7A11 axis offers a promising therapeutic strategy to enhance ferroptosis sensitivity and improve colon cancer outcomes. This evidence concerns the gene IGF2BP3 and colonic neoplasm.